The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
A Benefit-Risk Assessment of Benzbromarone in the Treatment of Gout: Was its Withdrawal from the Market in the Best Interest of Patients?
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Febuxostat Compared with Allopurinol in Patients with Hyperuricemia and Gout
Becker, M. A., Schumacher, H. R., Wortmann, R. L., MacDonald, P. A., Eustace, D., Palo, W. A., Streit, J., & Joseph-Ridge, N. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050373 · Cited by 1,357
Cited by
Hyperuricemia and its related diseases: mechanisms and advances in therapy
Du, L., Zong, Y., Li, H., Wang, Q., Xie, L., Yang, B., Pang, Y., Zhang, C., Zhong, Z., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01916-y · Cited by 631
Drug repurposing from an academic perspective
Oprea, T. I., Bauman, J. E., Bologa, C. G., Buranda, T., Chigaev, A., Edwards, B. S., Jarvik, J. W., Gresham, H. D., Haynes, M. K., Hjelle, B., et al. (2011) · Drug Discovery Today: Therapeutic Strategies · doi:10.1016/j.ddstr.2011.10.002 · Cited by 364
Physiology of Hyperuricemia and Urate-Lowering Treatments
Benn, C. L., Dua, P., Gurrell, R., Loudon, P., Pike, A., Storer, R. I., & Vangjeli, C. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00160 · Cited by 319
The British Society for Rheumatology Guideline for the Management of Gout
Hui, M., Carr, A., Cameron, S., Davenport, G., Doherty, M., Forrester, H., Jenkins, W., Jordan, K. M., Mallen, C. D., McDonald, T. M., et al. (2017) · Rheumatology · doi:10.1093/rheumatology/kex156 · Cited by 316
3D spheroid culture of hESC/hiPSC-derived hepatocyte-like cells for drug toxicity testing
Takayama, K., Kawabata, K., Nagamoto, Y., Kishimoto, K., Tashiro, K., Sakurai, F., Tachibana, M., Kanda, K., Hayakawa, T., Furue, M. K., et al. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2012.11.029 · Cited by 289
Metadata
- Authors
- Lee, M.-H. H., Graham, G. G., Williams, K. M., & Day, R. O.
- Venue
- Drug Safety
- Published
- 2008
- Volume
- 31
- Issue
- 8
- Pages
- 643-665
- ISSN
- 0114-5916 (ISSN-L)
- OpenAlex
- W2036508585
- Cited by
- 309
- References
- 1
- FWCI
- 8.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Benefit-Risk Assessment of Benzbromarone in the Treatment of Gout: Was its Withdrawal from the Market in the Best Interest of Patients? https://app.cochat.ai/papers/10.2165/00002018-200831080-00002
- The paper
- Lee, M.-H. H., Graham, G. G., Williams, K. M., & Day, R. O. (2008). A Benefit-Risk Assessment of Benzbromarone in the Treatment of Gout: Was its Withdrawal from the Market in the Best Interest of Patients? Drug Safety. https://doi.org/10.2165/00002018-200831080-00002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.